

## CURRICULUM VITAE

**Robert E. Dupuis, Pharm.D., BCPS**

### PERSONAL INFORMATION

**Address - Home:** 205 Kenilworth Place  
Chapel Hill, NC 27516

**Office:** Division of Pharmacotherapy  
School of Pharmacy  
University of North Carolina at Chapel Hill  
CB# 7360, Beard Hall  
Chapel Hill, North Carolina 27599-7360

**Contact:** (919) 966-6194; (919) 962-0644 FAX  
EMAIL: [re\\_dupuis@unc.edu](mailto:re_dupuis@unc.edu)  
Home: (919) 968-1329

### EDUCATION

Doctor of Pharmacy  
State University of New York at Buffalo  
Buffalo, New York  
June, 1982

Bachelor of Science in Pharmacy  
Northeastern University  
June 1979

### CERTIFICATION/LICENSURE

Board Certification in Pharmacotherapy  
North Carolina License #09828

### PROFESSIONAL EXPERIENCE

June 1995 to present	Clinical Associate Professor School of Pharmacy University of North Carolina at Chapel Hill
May 1989 to May 1995	Assistant Professor School of Pharmacy University of North Carolina at Chapel Hill
June 1985 to May 1989	Instructor School of Pharmacy University of North Carolina at Chapel Hill
January 1986 to June 1991; June 1994 to September 1995	Director Clinical Pharmacokinetics Service UNC Hospitals
July 1986 to present	Assistant Director of Toxicology Department of Laboratory Medicine UNC Hospitals

July 1982 to June 1985	Clinical Coordinator in Medicine and Pharmacokinetics Buffalo General Hospital Buffalo, New York
June 1984 to June 1985	Clinical Instructor School of Medicine State University of New York at Buffalo Buffalo, New York
October 1982 to June 1985	Clinical Instructor School of Pharmacy State University of New York at Buffalo Buffalo, New York
June 1979 to June 1980	Hospital Pharmacy Resident Moses Cone Memorial Hospital Greensboro, North Carolina

**Part-Time/Consultant**

1995 to present	Community Pharmacist Tom Jones Pharmacy Garner, NC
2003- present	Pharmacist Orange County Public Health Department Hillsborough, NC

**AWARDS AND HONORS**

"Access Award," presented by UNC-CH Learning Disabilities Services 2002

"Instructor/Preceptor of the Year," presented by  
Pharm.D. graduate class, 1987, 1990, 1993, 1995, 1998, 2000, 2001, 2003

"Professional Accomplishment Award," presented by SUNY at Buffalo School of Pharmacy 1998

**COMMITTEE APPOINTMENTS**

NIH Adult to Adult Living Donor Liver Transplant Consortium Liver Regeneration Subcommittee 2002 - present  
UNC Division of Pharmacotherapy Promotion and Reappointment Committee 2002 - present  
UNC School of Pharmacy Faculty Salary Committee 2002 – present  
UNC School of Pharmacy Honors Committee 1999- present (coChair)  
UNC School of Pharmacy Scholarship & Awards Committee 1999-present  
UNC Graduate Student Advisory Master's Committee Division of Pharmacotherapy & Division of Drug  
Development & Disposition, 1987– 2003  
ACCP Immunology/ Transplant Program Committee 2001  
ACCP Clinical Affairs Committee, 1998- 2000  
ASHP Immunology/ImmunoTherapeutics Fellowship Committee, 1996 – 00  
ACCP Industrial Relations Committee, 1996 - 1997  
UNC School of Pharmacy Faculty Development Committee, 1994 - 1998

## Curriculum Vitae

Robert E. Dupuis

Page 3

### EDITORIAL RESPONSIBILITIES

#### Reviewer/Contributor:

Annals of Pharmacotherapy (Editorial Board of Transplant section)  
PSAP Clinical Algorithms Handbook  
ASHP PharmPrep  
Pharmacotherapy Specialty Board  
Journal of Pharmacy Practice  
Archives of Pathology  
Renal Failure  
Clinical Chemistry

### PROFESSIONAL SOCIETY AFFILIATIONS

American College of Clinical Pharmacy  
American Society of Health-System Pharmacy  
Triangle Chapter of the American College of Clinical Pharmacy

### ADVISORY BOARDS

Astellas Pharmaceuticals  
Novartis Pharmaceuticals  
Roche Inc  
Sangstat Inc  
Sidmak Inc  
Wyeth-Ayerst Pharmaceuticals

### POSTDOCTORAL RESIDENTS/FELLOWS/GRADUATE STUDENTS (TRANSPLANTATION/CLINICAL PHARMACOKINETICS)

<u>Year</u>	<u>Resident/Fellow/Graduate Students</u>
1988	Stephanie Perry (Resident)
1989	Dorothy Maffei (Resident)
1990	Jorge Miranda (Fellow)
1991	Julie Kirk (Resident)
1991	Jorge Miranda (Fellow)
1993	Patrick Wire (Fellow)
1993	April Cooper (Resident)
1994	Howard Peckman (Grad Student)
1995	Toyin Sofowora (Grad Student)
1996	Angela Smith (Resident)
1997	Kimberly Hollar (Resident)
1998	Kimberly Hollar (Fellow)
1999	Andrea Ciminelli (Resident)
1999	Odin Naderer (Fellow)
1999	David Taber (Resident)
2000	Amy Fann (Resident)
2001	Greg Malat (Resident)
2002	Kevin Haynes (Fellow)
2002	Ruthann Conoley (Resident)
2003	Andrew Nelsen (Fellow)
2003	Derrick VanBeuge (Resident)
2004	Eric Williams (Fellow)
2004	Matt Harris (Resident)
2004	Kathryn Gillis (Fellow)

**PUBLICATIONS**

1. Naderer OJ, Dupuis RE, Heinzen E, Wiwattanawongsa K, Johnson MW, Smith PC. The influence of norfloxacin and metronidazole on the disposition of mycophenolate mofetil. *J Clin Pharmacol* 2005;45:219-226.
2. Taber DJ, Dupuis RE. Solid Organ Transplantation. In *Applied Therapeutics: The Clinical Use of Drugs*. 8<sup>th</sup> EDITION. Koda-Kimble M, Young L. 2004
3. Dupuis RE. Medical Management of Lung Transplant Recipients. In *Respiratory Pharmacotherapy Reference Guide*. 1<sup>st</sup> Edition. 2004
4. Taber DJ, Malat GE, Fann AL, Dupuis RE. Prediction of vancomycin pharmacokinetics and creatinine clearance after liver transplantation. *Ther Drug Mon* 2003;25:67-72
5. Malat GE, Dupuis RE, Kassman B, Rhoads JM, Freeman K, Lichtman S, Johnson MW, Gerber D, Andreoni K, Fair J. Tacrolimus-induced pain syndrome in a pediatric orthotopic liver transplant patient. *Ped Transplant* 2002;6:435-438.
6. Taber DJ, Dupuis RE, Fann AL, Andreoni K, Gerber D, Fair J, Johnson MW, Shrestha R. Tacrolimus dosing requirements and concentrations in living donor liver transplant recipients. *Liver Transplantation* 2002;8:219-223.
7. Joy MS, Hollar KD, Neyhart CD, Hogan SL, Dupuis RE, Finn WF, Dooley MA. Assessment of risk factors for bone disease in renal transplant recipients. *J Pharm Tech* 2002;18:54-62.
8. Dupuis RE, Taber DJ, Fann AL, Lumbert KP. Medical management considerations for patients with lung transplantation. *J Pharm Pract* 2001;14:258-276.
9. Wiwattanawongsa K, Heinzen EL, Kemp DC, Dupuis RE, Smith PC. Determination of mycophenolic acid and its phenol glucuronide metabolite in human plasma and urine by high-performance liquid chromatography. *J Chromat B* 2001;763:35-45.
10. Reid C, Dupuis RE, Fann AL, Taber DJ, Johnson MW, Fair J. Evaluation of calcium and vitamin D supplementation in liver transplant recipients. *Am J Transplant* 2001;1:421.
11. Dupuis RE. Solid Organ Transplantation. In *Applied Therapeutics: The Clinical Use of Drugs*. 7<sup>th</sup> EDITION. Koda-Kimble M, Young L. 2001
12. American College of Clinical Pharmacy Clinical Practice Affairs Committee. Practice guidelines for pharmacotherapy specialists. A position statement of the American College of Clinical Pharmacy. *Pharmacotherapy* 2000;20:487-490.
13. Taber D, Dupuis RE, Hollar KD, Stralzka AL, Johnson MW. Drug-drug interaction between chloramphenicol and tacrolimus in a liver transplant recipient. *Transplant Proc* 2000;32:660-662.
14. Ciminelli A, Dupuis RE, Williams D, Hollar KD. The role of the pharmacist in a multidisciplinary patient education program on a renal transplant service. *Am J Health Sys Pharm* 2000;57:767-768.
15. Taber DJ, Dupuis RE, Hollar KD, et al. Comparison of CMV prophylaxis and preemptive therapy in liver and kidney transplant recipients. *Transplantation* 2000;69:s181.

## Curriculum Vitae

Robert E. Dupuis

Page 5

16. Hollar KD, Zacks SL, Dupuis RE, et al. Prevalence of low bone mass and risk factors in patients awaiting liver transplantation. *Transplantation* 2000;69:s316.
17. Johnson MW, Salm J, Taber D, Schoots M, Hollar KD, Dupuis RE. Delayed use of tacrolimus in orthotopic liver transplant patients with renal insufficiency. *Transplantation* 2000;69:s216
18. Wiwattanawongsa K, Heinzen EL, Dupuis RE, Smith PC. Influence of antibiotics on the disposition of mycophenolic acid in the guinea pig. *AAPS* 1999;s420.
19. Naderer OJ, Dupuis RE, Wiwattanawongsa K, Campbell BJ, Hege SG, Smith PC, Johnson MW. Reduction
20. of plasma mycophenolic acid and its glucuronide concentrations with antibiotic treatment. *Clin Pharmacol Ther* 1999;65:159
21. Dupuis RE, Sredzienski ES. Tobramycin pharmacokinetics in patients with cystic fibrosis preceding and following lung transplantation. *Ther Drug Mon* 1999;21:161-165.
22. Hollar KD, Dupuis RE, Williams DW, Dennis BE, Joy MS. Corticosteroid-induced osteoporosis: assessment of potential risk and prescribed treatment in organ transplant recipients and patients with pulmonary disease. *Int Pharm Abstr*, 1998.
23. Joy MS, Hollar KD, Neyhard CD, Dooley MA, Hogan SL, Dupuis, RE, Finn WF. Risk factors for steroid induced bone disease in renal transplantation. *Transplantation* 1998; 65:150.
24. Hollar KD, Scott CS, Dupuis RE. Tobramycin Pharmacokinetics in a Pediatric Patient with Cystic Fibrosis Following Lung Transplantation. *J Ped Pharm Pract* 1998; 3:110-114.
25. Smith A, Dupuis R, Gott K. Conversion from Sandimmune to Neoral in stable lung transplant recipients. *Pharmacotherapy* 1997;17:202.
26. Lee B, Dupuis R, Gott K, Paradowski L, Aris R, Detterbeck F, Egan T. The effect of conversion from Sandimmune to Neoral on the pharmacokinetics of cyclosporine in lung transplant recipients with cystic fibrosis receiving chronic ketoconazole. *Pharmacotherapy* 1996;16:516-7.
27. Johnson M, Odell P, Dupuis R, Bunzendahl H, Fair J. The cost effectiveness of conversion of Sandimmune to Neoral in liver transplant recipients. *American Society of Transplant Physicians, Dallas, TX, May* 1996;18:647-53.
28. Peckman HJ, Dupuis RE, Sawyer WT, Brouwer KLR, Cross RE. Vancomycin serum concentrations in patients with renal dysfunction: A comparison of fluorescence polarization immunoassay and the enzyme-multiplied immunoassay technique. *Ther Drug Mon* 1996;18:647-53.
29. Wire PD, Dupuis RE, Lindley CL, Mohler DD, Bernard SO. Methotrexate disposition in a patient with an orthotopic neo-bladder with and without a urethral catheter cancer. *Pharmacotherapy* 1996;16:961-64.
30. Dupuis RE, Cooper A, Rosamond LJ, Campbell-Bright S. Delayed peak lithium concentrations in lithium overdose. *Ann Pharmacother* 1996;30:356-360.
31. Dupuis RE. *Solid Organ Transplantation In Applied Therapeutics: The Clinical Use of Drugs. 6th edition. Koda-Kimble M, Young L. 1995.*
32. Dupuis RE. Book review: *Basic Clinical Pharmacokinetics*. Third edition 1994. *Ann Pharmacotherapy* 1995;29:944.
33. Gunnarsson PS, Sawyer WT, Montague D, Williams ML, Dupuis RE, Caiola SM. Appropriate use of heparin: empiric versus nomogram based dosing. *Arch Int Med* 1995;155:526-532.

## Curriculum Vitae

Robert E. Dupuis

Page 6

34. Dupuis RE, Kirk JK. Therapeutic approaches to the treatment of hyperlipidemia in the transplant patient. *Ann Pharmacother* 1995;29:879-891.
35. Dupuis RE, Sofowora OO, Finn WF. Prediction of cyclosporine area under the concentration-time curve using limited sampling strategies. *Pharmacotherapy* 1994;14:372.
36. Baldwin JE, Dupuis RE, Wire PD. Cyclosporine clearance in patients with and without cystic fibrosis following lung transplantation. *Int Pharm Abst* 1994;31:2288.
37. Dupuis RE, Wire PD, Sredzienski ES. Tobramycin pharmacokinetics and dosing requirements in patients with cystic fibrosis preceding and following lung transplantation. *Int Pharm Abst* 1994;31:2291.
38. Kirk JK, Dupuis RE, Miles M, Gaddy GD, Williams DM, Miranda JM. Salivary Theophylline Monitoring: Reassessment and Clinical Considerations. *Ther Drug Mon* 1994;16:58-66.
39. Price T, Dupuis RE, Carr B, Stanczyk F, Lobo R, Droegemueller W. Single and multiple dose pharmacokinetics of a low dose oral contraceptive in women with chronic renal failure undergoing peritoneal dialysis.. *Am J Obstet Gynecol* 1993;168:1400-6.
40. Miles MV, Dupuis RE, Miranda-Massari JR, Soucie MP. Digibind interference with FPIA and ELIA digoxin methods. 3rd International Congress of Therapeutic Drug Monitoring and Clinical Toxicology, Philadelphia, PA, May, 1993.
41. Miranda-Massari JR, Miles MV, Soucie MJ, Dupuis RE. Comparison of digibind effects of digoxin concentrations with FPIA and ELIA methods. 21st American College of Clinical Pharmacology Meeting, September 1992. *J Clin Pharmacol* 1992;32:755.
42. Kirk JK, Dupuis RE, Miles MV, Miranda JR, Williams DM. Relationship between saliva and serum theophylline concentrations: A comparison of two assays and two saliva stimulation methods. Twenty-first Annual American College of Clinical Pharmacology Meeting. September 1992. *J Clin Pharmacol* 1992;32:754.
43. Breyer ED, Dupuis RE, Cross RE, Letzow CB, Chapman JF. Development and evaluation of an optimized HPLC assay for cyclosporine A (CsA) and two major metabolites. American Association of Clinical Chemists Meeting, July 1992. *Clin Chem* 1992;38:1003.
44. Breyer ED, Dupuis RE, Cross RE, Miranda JR, Chapman JF. Comparison between three types of specific whole blood cyclosporine A assays. American Association of Clinical Chemists Meeting, July 1992. *Clin Chem* 1992;38:1003.
45. Miles MV, Miranda-Massari J, Dupuis RE, Mill MR, Zaritsky AL, Nocera M, Lawless ST. Determination of salivary digoxin with a dry strip immunometric assay. *Ther Drug Mon* 1992;14:249-54.
46. Dupuis RE, Miranda-Massari J. Dialysis and Renal Transplantation. In: Workbook for Clinical Pharmacy and Therapeutics, Hart LL (ed), William and Wilkins, Baltimore, MD, 1992.
47. Matzke GR, Dupuis RE, Frye RF, Luke DR. Renal transplant therapy and dialysis. In: Clinical Pharmacy and Therapeutics. Fifth Edition. Herfindal ET, Copley DR, Hart LL (eds), William and Wilkins, Baltimore, MD, 1992.
48. Kirk JK, Dupuis RE, Miles MV, Williams DM, Miranda JM. Comparison of a dry reagent method with fluorescence polarization immunoassay for the determination of salivary theophylline concentrations. American College of Clinical Pharmacy Meeting, August 1992. *Pharmacotherapy* 1992;12:248.
49. Price T, Dupuis RE, Carr B, Stanczyk F, Lobo R, Droegemueller W. Multiple dose pharmacokinetics of a 35 ug ethinyl estradiol, 1 mg norethindrone oral contraceptive in women with chronic renal failure on peritoneal dialysis. Society for Gynecologic Investigation Meeting, March 1992.

## Curriculum Vitae

Robert E. Dupuis

Page 7

50. Miles MV, Zaritsky AL, Lawless St, Mill MR, Nocera MA, Dupuis RE. Digoxin monitoring in critically ill pediatric patients. American College of Clinical Pharmacology Meeting, J Clin Pharmacol 1991;31:851.
51. Dupuis RE, Miranda-Massari J. Anticonvulsants - Pharmacotherapeutic issues in the critically ill. AACN Clinical Issues in Critical Care Nursing 1991;2:639-656.
52. Dupuis RE. Bayesian forecasting, pharmacokinetics and therapeutic drug monitoring. In: Yearbook of Pathology and Clinical Pathology, 1991, pp. 251-254. Brinkhous KM, Dalldorf FG, Langdell RD, McLendon WW (eds.),
53. Roush MK, Dupuis R. Significance of the ciprofloxacin-antacid interaction. DICP, Annals of Pharmacother 1991;25:473-475.
54. Matzke GR, Frye RF, Dupuis RE, Carson SW. Optimization of vancomycin bayesian analysis: Initial population parameters (IPP) vs Forecasting Program. 12th Annual ACCP Meeting, Minneapolis, MN, August 1991. Pharmacotherapy 1991;11:267.
55. Dupuis RE, Miranda-Massari JR, Miles MV, Soucie M. Serial serum digoxin concentrations in patients receiving digoxin specific FAB fragments (Digibind): A comparison between FPIA and IMAT. 22nd Annual Southeastern Conference for Postgraduate Pharmacy Education and Training, Athens, GA, April 1991.
56. Dupuis R. Drug interactions with cyclosporine. NCSHP Newsletter; January 1991.
57. Price T, Dupuis, Pollack G, Mattern W, Stanczyk F, Lobo R, Dotters D, Droegemueller W. Single dose pharmacokinetics of a 35ug ethinyl estradiol, 1mg norethindrone combination oral contraceptive in women with chronic renal failure on CAPD. Society of Gynecologic Investigation Meeting, Dallas, TX, March 1990.
58. Dupuis R. Drug interference with serum creatinine measurements. NCSHP Newsletter, February 1990.
59. Dupuis R, Lichtman S, Pollack G: Acute valproic acid overdose: Clinical course and pharmacokinetic disposition of valproic acid and metabolites. Drug Safety and Adverse Drug Reactions 1990;5:65-71.
60. Manning J, Hak L, Dupuis R, Dukes G, Gilligan P. Effect of calcium & urea in peritoneal dialysis fluid on the in vitro killing of Pseudomonas aeruginosa by tobramycin. ASHP Midyear, Atlanta, GA, December 1989.
61. Dupuis R, Matzke G, Maddux F, O'Neil M. Vancomycin disposition during continuous arteriovenous hemofiltration. Clinical Pharmacy 1989;8:371-374.
62. Hak LJ, Sawyer WT, Pleasants RP, Dupuis RE, Sarver PJ. Relationship between aminoglycoside dose, serum concentration and changes in serum creatinine over time during routine therapy in a university hospital. American College of Clinical Pharmacy, August 1989. Pharmacotherapy 1989;9:189.
63. Howlet CM, Miles M, Cross R, Tennison M, Greenwood R, Dupuis R. Serum N-desmethylnethsuximide determination using a modified ethosuximide assay procedure. American Association of Clinical Chemists Meeting, July 1988. Clin Chem 1988;34:1255.
64. Dupuis R, Matzke G, Maddux F, O'Neil M: Vancomycin disposition during continuous arteriovenous hemofiltration. American Society of Hospital Pharmacists Midyear Clinical Meeting, December 1988. Inpharma 1989;26:543.
65. Pleasants R, Dupuis R, Sawyer W: Determination of tobramycin pharmacokinetic parameters by three

## Curriculum Vitae

Robert E. Dupuis

Page 8

- immunoassays. American Society of Hospital Pharmacists Midyear Clinical Meeting, December 1988. *Inpharma* 1989;26:546.
66. Tennison M, Miles MV, Pollack GM, Thorn MD, Dupuis R: Valproate metabolites and hepatotoxicity in an epileptic population. *Epilepsia* 1988; 29:543-547.
  67. Pleasants R, Sawyer W, Dupuis R: Alterations in population volume of distribution values for aminoglycosides. *Clin Pharm* 1986;5:872-873.
  68. Dupuis R, Slaughter R: Severe theophylline toxicity. *Am J Med* 1985;A76-A82.
  69. Tennison M, Miles MV, Pollack GM, Dupuis R: Valproic acid metabolites and hepatotoxicity in an epileptic population. American Epilepsy Society Meeting Proceedings, December 1987. *Epilepsia* 1987;28:627.
  70. Dupuis R, Pleasants R, Williams D, Calmes H: Use of a Bayesian program to predict serum theophylline concentrations in the critically ill patient. American Society of Hospital Pharmacists Midyear Clinical Meeting, December 1986.
  71. Dupuis R: Drug Interactions. In Pharmacotherapeutics: Nursing Practice in Progress, edited by M. Matheson, 1984.

## INVITED PRESENTATIONS

1. LongTerm Complications of Hyperlipidemia in Solid Organ Transplant Recipients. ACCP Annual Meeting, Albuquerque, NM, October 2002.
2. Update on Immunosuppression in Renal Transplantation. UNC School of Medicine Nephrology Conference, June and August 2002.
3. Influence of Liver Regeneration on Drug Metabolism after Living Donor Liver Transplantation. Whistler, BC, Canada, March 2002.
- 4.
5. Living Donor Liver Transplantation and Impact on Drug Therapy. UNC School of Medicine, GI & Hepatology Conference, March 2002.
6. Important Issues and Medical Management of Complications in Transplant Recipients. ACCP Annual Meeting, Tampa, FLA, October 2001.
7. The Role of Pharmacokinetics in the Management of Immunosuppressives in Organ Transplantation. Fujisawa regional meeting, Chapel Hill, NC, June 2001.
8. Overview of Immunosuppressive Protocols in Organ Transplant Recipients. Role of the Pharmacist. Marco Island, FLA, Jan 2001
9. Cardiovascular Risks Factors: The Role of New Immunosuppressants. ACCP Annual Meeting, Los Angeles, CA, November 2000.
10. The Role of the Transplant Pharmacist. Carolinas Medical Center, Charlotte, NC. October 1999.

## Curriculum Vitae

Robert E. Dupuis

Page 9

11. The New Immunosuppressives in Solid Organ Transplant. UNC Transplant Symposium, Chapel Hill, NC. September 1999.
12. Cyclosporine: Pharmacokinetics & Generic Substitution. UNC Comprehensive Transplant Center's Kidney Transplant Seminar. Chapel Hill, NC. August 1999.
13. Long Term Complications of Solid Organ Transplant Recipients. American Society of Health Systems Pharmacists Annual Meeting, Reno, Nevada. June 1999.
14. Update: Pharmacotherapy in Solid Organ Transplantation. UNC, November 1996.
15. Cyclosporine: The Old and New. Duke University Medical Center, Department of Pharmacy Conference, May 1996.
16. Pharmacotherapy in Kidney Transplantation. UNC Ambulatory Care Pharmacy Conference, May 1996. Drug Interactions Update. Area Health Education Center Continuing Education Program, Fayetteville, NC, February 1996.
17. Pharmacotherapy in the Elderly. Area Health Education Center Continuing Education Program, Burlington, NC, November 1995.
18. Tacrolimus. Transplant Recipients International Organization, Cary, NC, November 1995.
19. Medicine after Lung Transplantation. UNC Lung Transplant Support Group, Spring 1996 and Fall 1995.
20. Clinical Pearl: Cystic Fibrosis and the Lung Transplant. American Society of Hospital Pharmacists, Midyear Meeting, Miami, FL, December, 1994.
21. Food and Drug Interactions. Ninth Annual Pharmacy Practice Seminar, UNC School of Pharmacy, Wilmington, NC, September 1994.
22. Therapeutic Drug Monitoring. Eighth annual Pharmacy Practice Seminar, UNC School of Pharmacy, Wilmington, NC, September 1993.
23. Encounters in Solid Organ Transplantation. TCCP, Research Triangle Park, NC, September 1993.
24. Pharmacokinetics in the Critically Ill. Duke University Infectious Disease Update. Wilmington, NC, September, 1993
25. Ten Years of Cyclosporine in Transplantation. Virginia Medical Society Continuing Education Program. Danville, VA, April, 1993
26. Immunosuppressives in Heart Transplantation. UNC Hospitals Department of Nursing Program, Chapel Hill, NC, November 1992.
27. Renal Failure Workshop. Seventh Annual Pharmacy Practice Seminar, UNC School of Pharmacy and North Carolina Pharmaceutical Association, Wilmington, NC, September 1992.
28. Pharmacokinetics and Plasmapheresis. Miles Medical Supervisors Meeting, Miles Inc., Raleigh, NC, August 1992.
29. Pharmacokinetic Considerations in Special Populations. Pediatrics and Geriatrics. Glaxo Clinical Pharmaceutical Scientist Curriculum Program, Glaxo Inc., Chapel Hill, NC, May 1992.
30. Organ Transplantation Update: Pharmacology of Immunosuppression. UNC Hospitals Department of Nursing CE Program, Chapel Hill, NC, March 1992.

## Curriculum Vitae

Robert E. Dupuis

Page 10

31. Therapeutic Use of Monoclonal Antibodies. Glaxo Clinical Pharmaceutical Scientist Curriculum Program, Chapel Hill, NC, January 1992.
32. Inter and Intrasubject Variability in the Pharmacokinetics of Cyclosporine in Renal Transplants at UNC. Preliminary Analysis. Department of Medicine, Division of Nephrology, UNC, October 1991.
33. Immunosuppressant Therapy in Transplant Patients. Sixth Annual Pharmacy Practice Seminar, UNC School of Pharmacy and North Carolina Pharmaceutical Association, Wilmington, NC, September 1991.
34. Immunosuppressives in Adult Liver Transplantation. UNC Hospitals Department of Nursing CE Program, Chapel Hill, NC, September 1991.
35. Immunosuppressives in Pediatric Liver Transplantation. UNC Hospitals Department of Nursing CE Program, Chapel Hill, NC, June, July, August 1991.
36. Pharmacokinetics and Pharmacodynamic Changes in the Elderly. Northwest AHEC, Appalachian Geriatric Education Center, May 1991.
37. Lung Transplantation and the Role of Immunosuppressive Agents. UNC Department of Nursing CE Program, February 1991.
38. Immunosuppression in Heart Transplantation. UNC Department of Nursing CE Program, January 1991.
39. Bayesian Forecasting and Therapeutic Drug Monitoring. UNC Clinical Pathology Series, June 1990.
40. Principles of Antimicrobial Therapy IV: Aminoglycosides and Quinolones. Wake AHEC, Raleigh, NC, May 1990.
41. Antilymphocyte Antibodies (OKT3) in Transplantation. NCSHP Winter Meeting, High Point, NC, February 1990.
42. Antibiotic Drug Dosing in Renal Impairment. Roerig Teleconference, Chapel Hill, NC, November 1989.
43. Immunosuppressives in Organ Transplantation. American Association of Critical Care Nursing, Durham, NC, November 1989.
44. New Approach to Cyclosporine Monitoring & Dosing in Renal Transplants. Nephrology Conference, UNC Hospitals, October 1989.
45. Immunosuppressives in Heart Transplantation. UNC Department of Nursing CE Program, October 1989.
46. Comparison of Assay Methodologies for Measuring Cyclosporine. Department of Medicine, Division of Nephrology, UNC, March 1989.
47. Immunosuppressives in Cardiac Transplantation. Department of Nursing, NCMH, CE Program, January 1989.
48. Vancomycin Dosing in Critically Ill Patients. Critical Care Grand Rounds, Department of Medicine, UNC, November 1988.
49. The Value of Clinical Pharmacokinetic Services. Annual Meeting of the NC American Association of Clinical Chemists (AACC), Chapel Hill, September 1988.
50. Evaluation of Aminoglycoside Pharmacokinetic Software. Area Health Education Center (AHEC) Continuing Education (CE) Program, Rocky Mount, NC, November 1987.

## Curriculum Vitae

Robert E. Dupuis

Page 11

51. Pharmacokinetics of Vancomycin and Aminoglycosides. NCMH Department of Laboratory Medicine Continuing Education Program, October 1987.
52. The Value of Vancomycin Serum Concentrations. NCSHP Annual Fall Meeting, Raleigh, October 1987.
53. New Advances in Drug Therapy. NCSHP Meeting, Greensboro, September 1987.
54. Role of an Active Metabolite in Therapeutic Drug Monitoring. Pharmacy Grand Rounds, NCMH, April 1987.
55. Pentamidine - An Overview. Pharmacy Grand Rounds, NCMH, March 1987.
56. Pharmacokinetic Software - the Abbott System. Seminar on Microcomputers, Drug Information and Statistics, NCSHP Meeting, Greenville, November 1986.
57. Blood Collection in Therapeutic Drug Monitoring. North Carolina Society of Hospital Pharmacists (NCSHP) Annual Meeting, Clinical Pearls Session, Greensboro, October 1986.
58. The Role of Digoxin Antibody in the Treatment of Digoxin Toxicity. Pharmacy Grand Rounds, NCMH, September 1986.
59. Therapeutic Drug Monitoring. presented at Clinical Pharmacology Conference, Department of Medicine, UNC, October 1985.
60. Theophylline: An Update. presented at Pulmonary Grand Rounds, Department of Medicine, UNC, October 1985.

## GRANTS AND CONTRACTS

1. Co- Investigator. Restoration of Hepatic Function in Living Liver Donors: An A-2All Muticenter Ancillary Study. NIH \$250,000, 05-07.
2. Principal Investigator. An In Vivo Assessment of Changes in CYP450 Activities During Liver Regeneration Following Living Donor Liver Transplantation. UNC University Research Grant, \$3720, 05-07.
3. Principal Investigator. Determination of Cytochrome P450 Activities During Liver Regeneration in Donors and Recipients Following Living Donor Liver Transplantation. Fujisawa, \$20,000, 02-05.
4. Co-Investigator. Adult to Adult Living Donor Liver Transplantation. NIH, \$842,607, 02-09.
5. Co-Investigator. The Role of UGTs in Drug Disposition. NIH, \$875,000, 02-06.
6. Botanical Drug Interactions in HIV: Impact in Glucuronidation. \$250,000, NCAM, 04-06.
7. Principal Investigator. The Role of Intestinal UGTs in Drug Disposition. UNC School of Pharmacy Seed Grant, 2000.
8. Principal Investigator. The Pharmacokinetics of Mycophenolate in CF and non-CF Lung Transplant Recipients. Roche, 1998.
9. Principal Investigator. Pharmacokinetics and Pharmacodynamics of Mycophenolate in Liver Transplant

## Curriculum Vitae

Robert E. Dupuis

Page 12

- Recipients. Roche, 1998.
10. Principal Investigator. The Influence of Antibiotics on the Enterohepatic Recirculation of Mycophenolate Mofetil. UNC Faculty Seed Grant, 1997.
  11. Co-investigator. Comparison of CMV IVIG and Oral Ganciclovir Versus Oral Ganciclovir Alone for Prophylaxis in Kidney and Liver Transplant Recipients. Med Immune, Inc., 1997.
  12. Principal Investigator. The Pharmacokinetics of Cyclosporine Before and After Conversion of Neoral from Sandimmune in Lung Transplant Recipients With Cystic Fibrosis. UNC Faculty Seed Grant and Sandoz Pharmaceutical Corporation, 1995.
  13. Principal Investigator. Time Dependent Changes in the Pharmacokinetic and Pharmacodynamics of Morphine and Metabolites in Patients with Trauma and Burn Injuries. UNC Injury Prevention Research Center Grant, 1994.
  14. Principal Investigator. Survey of Transplant Recipient-Pharmacist Interactions, Sandoz Pharmaceutical Corporation, 1994.
  15. Co-Principal Investigator, A Comparative Study of the Pharmacokinetics of Morphine and Its Metabolites in Patients with End-Stage Renal Disease and In Normal Volunteers. UNC School of Pharmacy Faculty Seed Grant, 1993.
  16. Principal Investigator, Impact of a Novel Pharmacokinetic Dosing Model for Cyclosporine on Patient Outcome and Costs in Renal Transplant Patients. ASHP Research and Education Foundation Demonstration Grant 1989-1991.
  17. Principal Investigator, Pharmacokinetic Profiling of Cyclosporine in Renal Transplant Patients. North Carolina Memorial Hospital Innovative Research Grant 1989-1991.
  18. Principal Investigator, Comparison of a Dry Reagent Method with Fluorescence Polarization Immunoassay for the Determination of Salivary and Serum Theophylline Concentrations. Miles Inc, 1992.
  19. Principal Investigator, Evaluation of Two Immunoassays for the Determination of Salivary and Serum Digoxin Concentrations in Patients with Renal Failure. Miles Inc., 1992.
  20. Co-Principal Investigator, Impact of Computerized Pharmacokinetic Forecasting on Practitioner Competency, Kinetic Consultation Activity and Patient Outcome. ASHP Research and Education Foundation Demonstration Grant 1990-1992.
  21. Principal Investigator, Pharmacokinetic Modeling of Cyclosporine and Role of Metabolites in Renal Transplantation. UNC Junior Faculty Development Award 1990-1991.
  22. Co-Investigator, Bioavailability Study of Rifampin Suspension and Capsules. Carolina Pharmaceutical Products 1988.
  23. Co-Principal Investigator, Evaluation of Three Different Immunoassays for Determination of Tobramycin Serum Concentrations. Abbott Laboratories 1988.
  24. Principal Investigator, Evaluation of Theophylline Pharmacokinetic Software in Critically Ill Patients. Abbott Laboratories 1987.